Skip to main content
. 2020 Nov 20;38(1):47–59. doi: 10.1007/s10585-020-10064-w

Table 1.

Clinical features of the 26 GTN patients with distant metastasis treated at Zhejiang University School of Medicine Women’s Hospital from 1999 to 2019

Characteristics Patients
Age (years)
  < 40 17 (65.4%)
  ≥ 40 9 (34.6%)
Blood type
 A/+ 10 (38.5%)
 B/+ 6 (23.1%)
 AB/+ 2 (7.7%)
 O/+ 6 (23.1%)
 Unknown 2 (7.7%)
Antecedent pregnancy
 Molar pregnancy 6 (23.1%)
 Term pregnancy 9 (34.6%)
 Abortion 9 (34.6%)
 Ectopic pregnancy 2 (7.7%)
Interval (months)a
  ≤ 6 9 (34.6%)
 7–12 4 (15.4%)
  > 12 13 (50.0%)
HCG level before treatment (IU/L)
  ≤ 104 6 (23.1%)
  > 104–105 13 (50.0%)
  > 105 7 (26.9%)
The maximum diameter (cm) (different imaging tests)
  < 5 14 (53.8%)
  ≥ 5 12 (46.2%)
Number of tumor lesions
  ≤ 8 14 (53.8%)
  > 8 12 (46.2%)
Metastatic sites
 Lung 18 (69.2%)
 Brain 14 (53.8%)
 Hepatic 8 (30.8%)
 Gastrointestinal 4 (15.4%)
 Spleen 3 (11.5%)
 Renal 3 (11.5%)
 Pancreas 2 (7.7%)
 Adrenal gland 1 (3.8%)
 Other distant sites Gallbladder, pleura, peritoneum, abdominal wall, lymphonodus, skin, muscle, etc.
 Lung or reproductive organs with more other organs 21 (80.8%)
 Only special sites 5 (19.2%)
FIGO scoreb
 0–6 1 (3.8%)
 7–12 5 (19.2%)
 ≥ 13 6 (23.1%)
Chemoresponse
 Sensitive 15 (57.7%)
 Resistant 6 (23.1%)
 Dependent 5 (19.2%)
Primary chemotherapy regimen is EMA-CO or EP-EMA
 Yes 18 (69.2%)
 No 8 (30.8%)
Surgery
 Yes 19 (73.1%)
 No 7 (26.9%)
Pathological pattern
 Choriocarcinoma 9 (34.6%)
 ETT 4 (15.4%)
 PSTT 2 (7.7%)
 Invasive mole 3 (11.5%)
 Coexisting 2 (7.7%)
 Unknown 6 (23.1%)
Status
 No evidence of disease (NED) 15 (57.7%)
 Dead 7 (26.9%)
 Under treatment 2 (7.7%)
 Lost to follow up 2 (7.7%)

EMA-CO etoposide, methotrexate, dactinomycin-cyclophospha-mide, vincristine, EP-EMA etoposide, methotrexate, dactinomycin-etoposide, cisplatin, IU/L international units per liter; cm: centimeter

aInterval from the termination of last known pregnancy to the diagnosis of GTN

bThe FIGO prognostic scoring system was inapplicable to patients with ITT